Lb Pharmaceuticals Income Statement (2024-2026) | LBRX

Income Statement Sep2024 Dec2024 Mar2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 10.66M0.38M3.42M2.42M8.48M14.64M
Selling, General & Administrative (Quarter) 5.42M5.16M3.01M2.83M5.39M7.46M
Operating Expenses (Quarter) 16.08M5.54M6.43M5.25M13.87M22.10M
EBIT (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Non-operating items
Interest & Investment Income (Quarter) 0.38M0.30M0.24M0.71M2.80M2.85M
Non Operating Income (Quarter) 1.90M0.47M1.12M1.69M2.40M3.05M
Net income details
EBT (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Tax Provisions (Quarter) 0.00M0.00M
Profit After Tax (Quarter) -14.18M-5.07M-5.31M-3.60M-11.50M-19.05M
Income from Continuing Operations (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Consolidated Net Income (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Income towards Parent Company (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Net Income towards Common Stockholders (Quarter) -14.18M57.97M-5.31M-3.56M13.71M-19.05M
Additional items
EPS (Basic) (Quarter) -39.49-14.00-14.79-0.613.13-0.67
EPS (Weighted Average and Diluted) (Quarter) -39.49-14.00-14.79-0.613.13-0.67
Shares Outstanding (Weighted Average) (Quarter) 0.36M0.36M0.36M5.81M8.05M28.24M
Shares Outstanding (Diluted Average) (Quarter) 0.36M0.36M0.36M2.20M8.05M28.24M
EBITDA (Quarter) -14.18M-5.07M-5.31M-3.56M-11.47M-19.05M
Shares Outstanding (Quarter) 0.25M0.25M0.25M3.19M25.30M28.67M
Tax Rate (Quarter) -0.02-0.01